Zoladex Market Predicted for Major Growth with High CAGR by 2024-2031 - Tersera Therapeutics, Mithra Pharmaceuticals, Alvogen, AMW GmbH, AstraZeneca

Zoladex Market Research Report By DataM Intelligence: A comprehensive analysis of current and emerging trends provides clarity on the dynamics of the Zoladex market. The report employs Porter's Five Forces model to assess key factors such as the influence of suppliers and customers, risks posed by different entities, competitive intensity, and the potential of emerging entrepreneurs, offering valuable insights. Additionally, the report presents research data from various companies, including their benefits, gross margins, and strategic decisions in the global market, all conveyed through tables, charts, and infographics.

Download Free Sample PDF: https://datamintelligence.com/download-sample/zoladex-market

What is the projected growth rate (CAGR) of the Global Zoladex market from 2024 to 2031, and what is the market value expected to change by 2031?

The global zoladex market reached US$ 0.92 billion in 2022 and is expected to reach US$ 1.03 billion by 2031 growing with a CAGR of 1.4% during the forecast period 2024-2031.

What is Zoladex Market?

Zoladex, also known by its generic name goserelin, is a synthetic hormone used primarily in the treatment of hormone-sensitive cancers, such as prostate and breast cancer, as well as in certain gynecological conditions, including endometriosis and uterine fibroids. It functions as a gonadotropin-releasing hormone (GnRH) agonist, which works by initially stimulating the release of hormones from the pituitary gland, leading to a temporary increase in hormone levels. However, prolonged use results in decreased production of sex hormones (testosterone in men and estrogen in women), effectively suppressing tumor growth and alleviating symptoms associated with hormone-related disorders. Zoladex is typically administered via subcutaneous injection.

Growth Driver

Increasing Prevalence of Breast Cancer and Chemotherapy-Related Infertility Driving Growth in the Zoladex Market
The rising incidence of breast cancer, particularly cases associated with infertility due to chemotherapy, is significantly fueling the growth of the Zoladex market. Chemotherapy is a common treatment for breast cancer, but it is known to increase the risk of infertility. Factors such as the patient's age and the specific types and dosages of chemotherapy drugs used can further impact fertility outcomes. Consequently, ongoing research into the implications of chemotherapy on reproductive health is contributing to the demand for Zoladex as a treatment option.

Key Players:

Profiles of some of the major players in the global Zoladex market, which include:

Tersera Therapeutics, Mithra Pharmaceuticals, Alvogen, AMW GmbH, AstraZeneca, Luye Pharma, Atossa Therapeutics, Sanofi, Fosun Pharma, and Bachem. These companies are actively involved in research, development, manufacturing, and distribution of Zoladex products.

Industry Development:

On June 30, 2021, Aztiq Pharma Partners, a long-term investment fund focusing on pharmaceuticals, announced its successful fundraising of $100 million to facilitate the acquisition of newly issued shares in Alvogen US. The funds were used to acquire a 17% stake in Alvogen US at a pre-money valuation of $350 million from Fora, aimed at improving patient access to high-quality and affordable medications.

On June 24, 2021, Mithra, a company specializing in women's health, announced that it successfully renegotiated the earnouts related to two products in its Complex Therapeutic portfolio, including the Myring hormonal contraceptive ring and the biodegradable Zoreline implant. The Zoreline implant, administered subcutaneously, is utilized for the treatment of breast cancer, prostate cancer, and benign gynecological conditions such as endometriosis and uterine fibroids.

On July 29, 2022, the European Society for Medical Oncology reported in a study involving premenopausal women who tested positive for estrogen receptors (ER) that two years of adjuvant endocrine therapy provided a significant 20-year benefit. In the Stockholm segment of the Zoladex in Premenopausal individuals study (STO-5), premenopausal women with ER-positive breast cancer showed substantial long-term advantages after two years of treatment with tamoxifen, goserelin, and the combination, compared to those who did not receive adjuvant endocrine treatment. Furthermore, the study indicated that goserelin was beneficial for genomic high-risk patients in the early stages, while tamoxifen provided significant long-term benefits for genomic low-risk patients.

The purpose of the report is to offer a comprehensive analysis of the market, along with insightful conclusions, statistical data, historical information, market data that has been confirmed by the industry, and predictions based on a sound methodology. By identifying and examining market segments and forecasting global market size, the study also contributes to understanding the dynamics and structure of the global Zoladex market.

Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=zoladex-market

Market Segments:

The report covers the segmentation of the market into different segments based on various classifications such as applications, end users, product types, and others. The segmentation is divided into two sections, one for development and the other for different roles, needs, and behaviours.

By Dosage: 3.6 mg, 10.8 mg

By Application: Prostate Cancer, Breast Cancer, Endometriosis, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Regional Break out:

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/zoladex-market

Key Features

➧ Gain deep insights into market dynamics, trends, and opportunities to stay ahead in a competitive landscape.

➧ Track competitor's movements in real time, allowing you to swiftly adapt strategies and remain competitive.

➧ Compare your performance with industry leaders to identify gaps, strengths, and areas for improvement.

➧ Stay updated with emerging market trends, technological advancements, and customer behaviour to refine your strategy.

➧ Receive actionable insights and recommendations to drive your business toward growth and long-term success.

➧ Tailor competitive intelligence to your unique business needs, ensuring relevant and focused analysis.

➧ Evaluate supply chain efficiency and logistics strategies to optimize operations and minimize disruptions.

➧ Understand key players, stakeholders, and partnerships to navigate the competitive landscape more effectively.

➧ Identify and target specific market segments with detailed intelligence on customer preferences and behaviours.

➧ Stay informed on regulatory changes and legal requirements impacting your industry to ensure compliance and mitigate risks.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.